Cambridge Healthtech Institute’s 2nd Annual
Bispecific Antibodies for Cancer Immunotherapy
Engineering Next-Generation Biotherapeutics in Immuno-Oncology
August 6-7, 2019
Engaging multiple receptors with bispecific biologics offers the potential to improve upon single-agent checkpoint blockade and promises to be the next generation of immunotherapy. Cambridge Healthtech Institute’s Second Annual Bispecific Antibodies
for Cancer Immunotherapy conference will showcase preclinical, translational and clinical studies on using bispecific antibodies for dual blockade of checkpoint targets, T-cell-redirecting bispecific biologics, overcoming T-cell exhaustion, as well
as strategies to improve efficacy and reduce toxicity, and engineer the next generation of bi- and multi-specific biologics.
Bispecific T-Cell Engaging Molecules: Mechanism of Action and Activity in Hematological Malignancies
Tara Arvedson, PhD, Director, Oncology Research, Amgen
Multiple Avenues to T-Cell Activation with Bispecific Antibodies
John Desjarlais, PhD, Senior Vice President, Research, CSO, Xencor
COBRAs – Development of a Potent, Conditionally Active Bispecific T-Cell Engager Platform
Bob DuBridge, PhD, EVP, Research & CTO, Maverick Therapeutics
Development of a Novel Bispecific Immune Modulating Antibody Targeting PD-L1 and CD27
Joel Goldstein, PhD, Senior Director, R&D, Celldex Therapeutics
Unbiased Functional Screening Unlocks Novel Biology for Targeted and IO Bispecific Antibodies
Mark Throsby, PhD, Executive Vice President & CSO, Merus NV
Unleash the Potential of Multispecific Antibodies to Fight Cancer
Jijie Gu, PhD, Director, Immunology Target Validation & Lead Discovery, Research Fellow, Biologics Research, AbbVie
A Novel, Monovalent Multi-Specific Antibody-Based Molecule that Simultaneously Modulates PD-L1 and 4-1BB Exhibits Potent Anti-Tumoral Activity In Vivo
Alexandre Simonin, PhD, Director, mAb Discovery, Numab Innovation AG
Targeting T Cell Agonists to the Tumor Environment with Multi-Specific Human Heavy Chain Antibodies
Wim van Schooten, PhD, CSO, TeneoBio
For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com
For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com